ENANTA PHARMACEUTICALS INC 8-K

What Happened Enanta Pharmaceuticals, Inc. announced on July 2, 2026 that it entered into an Open Market Sale Agreement with Jefferies LLC as sales agent to sell shares of its common stock. The offering is being made under Enanta’s Form S-3 shelf registration (filed Feb 11, 2026; declared effective Feb 20, 2026, Reg. No. 333-293390) and a prospectus supplement dated July 2, 2026. The company may offer and sell up to $75,000,000 aggregate principal amount of common stock in an “at-the-market” offering; Enanta is not obligated to sell any shares.

Key Details

• Agreement date: July 2, 2026; sales agent: Jefferies LLC.
• Maximum aggregate offering amount: up to $75,000,000 of common stock.
• Sales method: “at-the-market” offerings (including sales on Nasdaq or other trading markets) per Rule 415(a)(4).
• Agent fee: up to 3.0% of gross sales price; Enanta granted customary indemnification to the agent.
• The Sales Agreement is filed as Exhibit 1.1; legal opinion of Foley Hoag LLP is filed as Exhibit 5.1.

Why It Matters The agreement gives Enanta a flexible, on‑demand way to raise equity capital when market conditions are favorable, without a firm commitment to sell. If the company does sell shares under this program, it will increase shares outstanding and could dilute existing shareholders; investors should watch for future transaction notices and prospectus supplements disclosing any actual sales and terms.